Oxana Megherea is a pharmacist who is specialized in Oncology in Cherry Hill, New Jersey. Patients can reach her at 1721 Country Club Dr, Cherry Hill or contact her on 267-506-7870. Active license number of Oxana Megherea is RP454696 for Oncology in Pennsylvania. Oxana Megherea is a licensed pharmacist who has demonstrated specialized knowledge and skill in developing, recommending, implementing, monitoring, and modifying pharmacotherapeutic plans to optimize outcomes in patients with malignant diseases.
Complete Profile:
Oxana Megherea speciality, credentials, practice address, contact phone number and fax are as below. Patients can call on the below given phone number for enquiries.
Name:
Oxana Megherea
Specialization:
Oncology
Credentials:
PHARMD
Gender:
Female
Location:
1721 Country Club Dr, Cherry Hill, New Jersey, 08003-3448
Phone:
267-506-7870
Professional Identification Codes:
NPI number stands for National Provider Identifier which is a unique 10-digit identification number issued to health care providers in the United States by the Centers for Medicare and Medicaid Services (CMS).
NPI details of Oxana Megherea are as mentioned below.
NPI Number:
1053167494
NPI Enumeration Date:
26 Apr, 2024
NPI Last Update On:
26 Apr, 2024
Medical Licenses:
Pharmacists can have one or more medical licenses for different specialities in the same state or different states. Related medical licenses for Oxana Megherea are as mentioned below.
Specialization
License Number
State
Status
Oncology
RP454696
Pennsylvania
Primary
Business Mailing Address:
Business mailing address can be used for mailing purpose only, for visiting purpose patients need to refer above mentioned address.
Address:
1721 Country Club Dr, Cherry Hill, New Jersey
Zip:
08003-3448
Phone Number:
--
Fax Number:
--
Patients can reach Oxana Megherea at 1721 Country Club Dr, Cherry Hill, New Jersey or can call on phone at 267-506-7870.
Comments/ Reviews:
*Data of this site is collected from Medicare & Medicaid Services (CMS) and NPPES. Last updated on 09 December, 2024.